Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 8;2(1):vdaa112. doi: 10.1093/noajnl/vdaa112

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 2. — Bevacizumab therapy increases EMP2 levels. (A) Protein expression of EMP2 was visualized using standard IHC in clinical samples before and following bevacizumab treatment and eventual resistance. The expression pattern from 2 patients is shown. Magnification: 200×. Scale bar = 100 µm. (B and C) Protein expression of EMP2 in clinical samples increased after bevacizumab therapy in both unpaired (B) and paired (C) analyses. (D) Increase in protein expression was positively correlated with length of bevacizumab therapy.